...A. And this year, we gained approval for pediatric functional constipation in kids 6 to 17. B. This year, we acquired VectivBio and apraglutide which is really an innovative GLP-2 that I'll share with -- share some of the information with you today and also securing CNP-104, which we believe could be a disease-modifying agent for primary biliary cholangitis. C. This year, we had guided originally to an EBITDA of over $250 million, which we would have exceeded without the purchase of apraglutide, but it was just a tremendous opportunity for us to strengthen our pipeline. D. And obviously, with the addition of apraglutide in CNP-104, our financial outlook looks very different. E. While LINZESS is a $1 billion drug, we share that with AbbVie. F. So we basically secure about a little over $400 million in revenue, which we see growing over time as LINZESS continues to thrive in the marketplace. G. We certainly look at succeeding $1 billion by the end of the decade and certainly far beyond that...
